US 12,220,401 B2
Compounds useful as kinase inhibitors
Nicolas Guisot, Cheshire (GB)
Assigned to Loxo Oncology, Inc., Indianapolis, IN (US)
Filed by Loxo Oncology, Inc., Indianapolis, IN (US)
Filed on Jul. 31, 2023, as Appl. No. 18/362,249.
Application 18/362,249 is a continuation of application No. 17/525,350, filed on Nov. 12, 2021, granted, now 11,826,351.
Application 17/525,350 is a continuation of application No. 17/122,103, filed on Dec. 15, 2020, granted, now 11,471,441, issued on Oct. 18, 2022.
Application 17/122,103 is a continuation of application No. 15/930,657, filed on May 13, 2020, granted, now 10,918,622, issued on Feb. 16, 2021.
Application 15/930,657 is a continuation of application No. 16/063,542, granted, now 10,695,323, issued on Jun. 30, 2020, previously published as PCT/GB2016/053968, filed on Dec. 16, 2016.
Claims priority of application No. 1522245 (GB), filed on Dec. 16, 2015; and application No. 1613945 (GB), filed on Aug. 15, 2016.
Prior Publication US 2023/0372298 A1, Nov. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/02 (2006.01); C07D 231/14 (2006.01); C07D 231/38 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 403/04 (2006.01); C07D 405/04 (2006.01); C07D 405/06 (2006.01); C07D 405/08 (2006.01); C07D 405/14 (2006.01); C07D 413/06 (2006.01); C07D 417/04 (2006.01)
CPC A61K 31/415 (2013.01) [A61K 31/4155 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/02 (2018.01); C07D 231/14 (2013.01); C07D 231/38 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 403/04 (2013.01); C07D 405/04 (2013.01); C07D 405/06 (2013.01); C07D 405/08 (2013.01); C07D 405/14 (2013.01); C07D 413/06 (2013.01); C07D 417/04 (2013.01)] 6 Claims
 
1. A compound of the formula:

OG Complex Work Unit Chemistry
wherein * indicates a chiral center, or a pharmaceutically acceptable salt thereof.